Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Kathleen M Wyvill"'
Autor:
Diana V. Pastrana, Alberto Peretti, Nicole L. Welch, Cinzia Borgogna, Carlotta Olivero, Raffaele Badolato, Lucia D. Notarangelo, Marisa Gariglio, Peter C. FitzGerald, Carl E. McIntosh, Jesse Reeves, Gabriel J. Starrett, Valery Bliskovsky, Daniel Velez, Isaac Brownell, Robert Yarchoan, Kathleen M. Wyvill, Thomas S. Uldrick, Frank Maldarelli, Andrea Lisco, Irini Sereti, Christopher M. Gonzalez, Elliot J. Androphy, Alison A. McBride, Koenraad Van Doorslaer, Francisco Garcia, Israel Dvoretzky, Joceline S. Liu, Justin Han, Philip M. Murphy, David H. McDermott, Christopher B. Buck
Publikováno v:
mSphere, Vol 3, Iss 6 (2018)
ABSTRACT Several immunodeficiencies are associated with high susceptibility to persistent and progressive human papillomavirus (HPV) infection leading to a wide range of cutaneous and mucosal lesions. However, the HPV types most commonly associated w
Externí odkaz:
https://doaj.org/article/23f9f824fd734e23af44698af7c43b3a
Autor:
Robert Yarchoan, Denise Whitby, Giovanna Tosato, William Douglas Figg, Seth M. Steinberg, Kathryn Lurain, Anaida Widell, Priscila Goncalves, Kathleen M. Wyvill, Mark N. Polizzotto, Thomas S. Uldrick, Ramya Ramaswami
Kaplan-Meier curve of duration of response among 9 responders on the study, measured from the date of response (as compared with baseline) till progression or censorship when patient follow-up ended. Median time to progression was not reached. Hatch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b205133a8589475809d53b14dc086b
https://doi.org/10.1158/1078-0432.22471605
https://doi.org/10.1158/1078-0432.22471605
Autor:
Robert Yarchoan, Thomas S. Uldrick, Denise Whitby, Seth M. Steinberg, Priscila Goncalves, Jomy George, Anaida Widell, Kathleen M. Wyvill, Kathryn Lurain, Mark N. Polizzotto, Ramya Ramaswami
Supplementary Table from Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab1784d3a5b61ae2ca2ab98e8898763
https://doi.org/10.1158/1078-0432.22486467
https://doi.org/10.1158/1078-0432.22486467
Autor:
Robert Yarchoan, Thomas S. Uldrick, Denise Whitby, Seth M. Steinberg, Priscila Goncalves, Jomy George, Anaida Widell, Kathleen M. Wyvill, Kathryn Lurain, Mark N. Polizzotto, Ramya Ramaswami
Supplementary Figure from Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b01b7cf64a651016c09fe653b33722c
https://doi.org/10.1158/1078-0432.22486470.v1
https://doi.org/10.1158/1078-0432.22486470.v1
Autor:
Robert Yarchoan, Denise Whitby, Giovanna Tosato, William Douglas Figg, Seth M. Steinberg, Kathryn Lurain, Anaida Widell, Priscila Goncalves, Kathleen M. Wyvill, Mark N. Polizzotto, Thomas S. Uldrick, Ramya Ramaswami
Purpose:VEGF-A is important in the pathogenesis of Kaposi sarcoma, and bevacizumab has a response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with Kaposi sarcoma.Patients and Methods:Patients with Ka
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4f444920e13540146449021ebc6d4a
https://doi.org/10.1158/1078-0432.c.6527946
https://doi.org/10.1158/1078-0432.c.6527946
Autor:
Robert Yarchoan, Denise Whitby, Giovanna Tosato, William Douglas Figg, Seth M. Steinberg, Kathryn Lurain, Anaida Widell, Priscila Goncalves, Kathleen M. Wyvill, Mark N. Polizzotto, Thomas S. Uldrick, Ramya Ramaswami
Supplementary Table 2: Analysis of changes in serum VEGF-A and inflammatory cytokines between responders and non-responders after 6 cycles of treatment with bevacizumab and liposomal doxorubicin. *P values are for the difference between responders an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96e15ef349123e7621638b25438e5189
https://doi.org/10.1158/1078-0432.22471599.v1
https://doi.org/10.1158/1078-0432.22471599.v1
Autor:
Robert Yarchoan, Denise Whitby, Giovanna Tosato, William Douglas Figg, Seth M. Steinberg, Kathryn Lurain, Anaida Widell, Priscila Goncalves, Kathleen M. Wyvill, Mark N. Polizzotto, Thomas S. Uldrick, Ramya Ramaswami
Diagram to represent the treatment course and responses among patients treated within the study. *Patient had progressive disease of cutaneous KS but continued with treatment due to improvement in symptomatic pulmonary KS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735a00c7efea22529893f81c12f3d609
https://doi.org/10.1158/1078-0432.22471608
https://doi.org/10.1158/1078-0432.22471608
Autor:
Robert Yarchoan, Kathryn Lurain, Denise Whitby, Ramya Ramaswami, Mark N. Polizzotto, Anaida Widell, Thomas S. Uldrick, Jomy M. George, Seth M. Steinberg, Priscila H. Goncalves, Kathleen M. Wyvill
Publikováno v:
Clin Cancer Res
Purpose:Kaposi sarcoma (KS) is caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). KS, which develops most frequently among people with HIV, is generally treated with chemotherapy, but these drugs have acute and cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b8878facf543203a2f9b327696ee461
https://doi.org/10.1158/1078-0432.ccr-21-3364
https://doi.org/10.1158/1078-0432.ccr-21-3364
Autor:
Joanna Sztuba-Solinska, Elena M. Cornejo Castro, Nazzarena Labo, Lynne McNamara, Robert Yarchoan, Stuart F. J. Le Grice, Patrick MacPhail, Vickie Marshall, Karen Aleman, Kathleen M. Wyvill, Denise Whitby, Thomas S. Uldrick, Mark N. Polizzotto
Publikováno v:
Oncotarget
// Vickie A. Marshall 1 , Nazzarena Labo 1 , Joanna Sztuba-Solinska 2, 6 , Elena M. Cornejo Castro 1 , Karen Aleman 3 , Kathleen M. Wyvill 3 , Lynne McNamara 4 , Stuart F.J. Le Grice 2 , Robert Yarchoan 3 , Thomas S. Uldrick 3 , Patrick MacPhail 5 ,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba92624a83ecee6215145de814ba644
https://doi.org/10.18632/oncotarget.26321
https://doi.org/10.18632/oncotarget.26321
Autor:
Priscila H. Goncalves, Thomas S. Uldrick, Mark N. Polizzotto, Ramya Ramaswami, Denise Whitby, Seth M. Steinberg, Giovanna Tosato, Anaida Widell, Robert Yarchoan, William D. Figg, Kathryn Lurain, Kathleen M. Wyvill
Publikováno v:
Clin Cancer Res
Purpose: VEGF-A is important in the pathogenesis of Kaposi sarcoma, and bevacizumab has a response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with Kaposi sarcoma. Patients and Methods: Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb18790714208b9b2b055f17072c583
https://doi.org/10.1158/1078-0432.ccr-18-3528
https://doi.org/10.1158/1078-0432.ccr-18-3528